An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new piece in Psychology Today gathered expert advice about how GLP-1 drugs — the class that includes medicines like Ozempic and Wegovy — interact with eating disorders. The article doesn’t announce a single dramatic discovery. Instead, it summarizes concerns and recommendations from clinicians who treat people with eating disorders as these weight-loss drugs become more common. It’s aimed at patients, families, and clinicians trying to navigate a complicated, fast-changing space. GLP-1 drugs are medicines that mimic a natural hormone called GLP-1 (glucagon-like peptide-1). That hormone helps control appetite and digestion. In practice, these drugs tend to make people feel less hungry, make meals less appealing, and slow how fast the stomach empties. They were developed for diabetes and later approved at higher doses for weight loss. To someone unfamiliar with the word “peptide,” think of it as a small protein-like molecule that sends a signal in the body. The experts in the article mainly warn that GLP-1 drugs can complicate the diagnosis and treatment of eating disorders. Most of what’s discussed is clinical observation and early experience, not large randomized trials. Clinicians report a range of effects: for some patients with binge eating, reduced appetite has helped reduce episodes; for others, the drugs can mask underlying disordered eating or trigger unhealthy restriction because the medication curbs hunger cues. The piece emphasizes that individual responses vary and that there isn’t definitive research yet showing long-term risks or benefits specifically in people with active or past eating disorders. This matters because more people are using GLP-1 drugs, and some of those people either have an existing eating disorder or are vulnerable to one. If you or someone you love has a history of anorexia, bulimia, binge-eating, or disordered eating thoughts, starting one of these medications should involve careful discussion with a clinician who knows both eating disorders and these drugs. For people without eating-disorder histories, it’s still worth being mindful: changes in appetite, mood, and body image can affect mental health and behaviors around food. The main caveats are that experts don’t have all the answers yet. Potential side effects of GLP-1 drugs include nausea, GI upset, and changes in how you experience hunger and fullness. For people with a history of restrictive eating, these medications could encourage further restriction or make it harder to notice dangerous patterns. They’re prescription drugs approved for certain conditions, not over-the-counter remedies, and decisions about starting or stopping them should be made with medical guidance. Clinicians in the article recommend monitoring mental health, communicating openly about eating behaviors, and involving eating-disorder specialists when needed. Bottom line: GLP-1 drugs can help some people but may complicate or worsen eating-disorder issues for others, so expert oversight and honest conversations are essential.
Source: Psychology Today